EUVIMEDEUVIMED entdecken
Crossref

Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence

Minjie Luo iD, Derek Wong, Kristin Zelley, Jinhua Wu, Jeffery Schubert, Elizabeth H Denenberg, Elizabeth A Fanning, Jiani Chen, Daniel Gallo, Netta Golenberg, Maha Patel, Laura K Conlin und 7 weitere

JNCI: Journal of the National Cancer Institute · 01.08.2024 · 116 (8) · 1356-1365

DOI: 10.1093/jnci/djae102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 03.05.2024. Verfasst von Minjie Luo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Germ-Line Mutation, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TP53 alterations are common in certain pediatric cancers, making identification of putative germline variants through tumor genomic profiling crucial for disease management.

Methods

We analyzed TP53 alterations in 3123 tumors from 2788 pediatric patients sequenced using tumor-only or tumor-normal paired panels. Germline confirmatory testing was performed when indicated. Somatic and germline variants were classified based on published guidelines.

Results

In 248 tumors from 222 patients, 284 tier 1/2 TP53 sequence and small copy number variants were detected. Following germline classification, 86.6% of 142 unique variants were pathogenic or likely pathogenic. Confirmatory testing on 118 patients revealed germline TP53 variants in 28 of them (23 pathogenic or likely pathogenic and 5 of uncertain significance), suggesting a minimum Li-Fraumeni syndrome incidence of 0.8% (23/2788) in this cohort, 10.4% (23/222) in patients with TP53 variant–carrying tumors, and 19.5% (23/118) with available normal samples. About 25% (7/28) of patients with germline TP53 variants did not meet Li-Fraumeni syndrome diagnostic or testing criteria, while 20.9% (28/134) with confirmed or inferred somatic origins did. TP53 biallelic inactivation occurred in 75% of germline carrier tumors and was also prevalent in other groups, causing an elevated tumor-observed variant allelic fraction. Somatic evidence, however, including low variant allele fraction correctly identified only 27.8% (25/90) of patients with confirmed somatic TP53 variants.

Conclusion

The high incidence and variable phenotype of Li-Fraumeni syndrome in this cohort highlights the importance of assessing germline status of TP53 variants identified in all pediatric tumors. Without clear somatic evidence, distinguishing somatic from germline origins is challenging. Classifying germline and somatic variants should follow appropriate guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationTumor Suppressor Protein p53Li-Fraumeni SyndromeNeoplasmsHumansChildMaleFemaleChild, PreschoolAdolescentGenetic Predisposition to DiseaseDNA Copy Number VariationsGenetic TestingPrevalenceInfant

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
  • Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Minjie Luo, Kara N Maxwell

Zitieren

APA

Luo, M., Wong, D., Zelley, K., Wu, J., Schubert, J., Denenberg, E. H., Fanning, E. A., Chen, J., Gallo, D., Golenberg, N., Patel, M., Conlin, L. K., Maxwell, K. N., Wertheim, G. B., Surrey, L. F., Zhong, Y., Brodeur, G. M., MacFarland, S. P., & Li, M. M. (2024). Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence. JNCI: Journal of the National Cancer Institute, 116(8), 1356-1365. https://doi.org/10.1093/jnci/djae102

Vancouver

Luo M, Wong D, Zelley K, Wu J, Schubert J, Denenberg EH, et al. Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence. JNCI: Journal of the National Cancer Institute. 2024;116(8):1356-1365. doi:10.1093/jnci/djae102

BibTeX
@article{Luo2024,
  author = {Luo, Minjie and Wong, Derek and Zelley, Kristin and Wu, Jinhua and Schubert, Jeffery and Denenberg, Elizabeth H and Fanning, Elizabeth A and Chen, Jiani and Gallo, Daniel and Golenberg, Netta and Patel, Maha and Conlin, Laura K and Maxwell, Kara N and Wertheim, Gerald B and Surrey, Lea F and Zhong, Yiming and Brodeur, Garrett M and MacFarland, Suzanne P and Li, Marilyn M},
  title = {Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {8},
  pages = {1356--1365},
  doi = {10.1093/jnci/djae102}
}
Kostenlos starten →